{
    "clinical_study": {
        "@rank": "74049", 
        "arm_group": {
            "arm_group_label": "Treatment", 
            "arm_group_type": "Experimental", 
            "description": "Treatment with the ForSight VISION5 Product in both eyes (OU)."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate safety and comfort of the ForSight VISION5 product\n      when used for up to 13 months."
        }, 
        "brief_title": "An Open-Label Extension Study to Evaluate the Safety of the ForSight VISION5 Product", 
        "completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Primary Open-Angle Glaucoma", 
            "Ocular Hypertension"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Glaucoma", 
                "Glaucoma, Open-Angle", 
                "Hypertension", 
                "Ocular Hypertension"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Completed FSV5-002 study.\n\n          2. Written informed consent prior to any study procedure.\n\n          3. Willingness to comply with the visit schedule.\n\n        Exclusion Criteria:\n\n          1. Participation in an investigational drug or device study other than FSV5-002 within\n             the past 6 months or anticipated participation during the study period.\n\n          2. Subjects who will require contact lens use during the study period.\n\n          3. Any condition or situation (such as uncontrolled systemic disease) that, in the\n             Investigator's opinion, might confound the results of the study, may put the subject\n             at significant risk or might interfere with the subject's ability to participate in\n             the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "126", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 18, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02143843", 
            "org_study_id": "FSV5-003"
        }, 
        "intervention": {
            "arm_group_label": "Treatment", 
            "description": "ForSight VISION5 Product used continuously for 7 months, then replaced with a new ForSight VISION5 Product and used continuously for another 6 months.", 
            "intervention_name": "ForSight VISION5 Product", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 18, 2014", 
        "number_of_arms": "1", 
        "official_title": "An Open-Label Extension (OLE) Study to Evaluate the Safety of the ForSight VISION5 Product in Subjects With Open-Angle Glaucoma or Ocular Hypertension Who Have Completed Study FSV5-002", 
        "other_outcome": [
            {
                "measure": "Patient-reported comfort assessment", 
                "safety_issue": "No", 
                "time_frame": "13 months"
            }, 
            {
                "measure": "Maintenance of IOP-reduction", 
                "safety_issue": "No", 
                "time_frame": "13 months"
            }, 
            {
                "measure": "Frequency of rescue treatment", 
                "safety_issue": "No", 
                "time_frame": "13 months"
            }, 
            {
                "measure": "Retention duration of the ForSight VISION5 Product", 
                "safety_issue": "No", 
                "time_frame": "13 months"
            }
        ], 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Incidence and severity of ocular and non-ocular adverse events", 
            "measure": "Safety", 
            "safety_issue": "Yes", 
            "time_frame": "13 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02143843"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Intraocular Pressure (IOP)", 
            "measure": "Intraocular Pressure (IOP)", 
            "safety_issue": "No", 
            "time_frame": "13 months"
        }, 
        "source": "ForSight Vision5, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "ForSight Vision5, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}